New strategies in peripheral T-cell lymphoma: Understanding tumor biology and developing novel therapies

Kieron Dunleavy, Richard L. Piekarz, Jasmine Zain, John Edward Janik, Wyndham H. Wilson, Owen A. O'Connor, Susan E. Bates

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Peripheral T-cell lymphomas (PTCL) constitute a group of heterogeneous diseases that are uncommon, representing, in Western countries, only approximately 10% of all non-Hodgkin lymphomas. They are typically associated with a poor prognosis compared with their B-cell counterparts and are much less well understood with respect to tumor biology, owing to their rarity and biologic heterogeneity, and to the fact that characteristic cytogenetic abnormalities are few compared with B-cell lymphomas. Although the outcome for patients with anaplastic large cell lymphoma (ALCL), particularly anaplastic lymphoma kinase (ALK)-positive ALCL, is good, other types of PTCLs are associated with a poor prognosis, even with aggressive anthracycline-based chemotherapy. In this respect, there is a need for new approaches in these diseases, and this review focuses on and explores recent experience with novel therapies in PTCL.

Original languageEnglish (US)
Pages (from-to)5608-5617
Number of pages10
JournalClinical Cancer Research
Volume16
Issue number23
DOIs
StatePublished - Dec 1 2010

Fingerprint

Peripheral T-Cell Lymphoma
Anaplastic Large-Cell Lymphoma
Anthracyclines
B-Cell Lymphoma
Chromosome Aberrations
Non-Hodgkin's Lymphoma
Neoplasms
B-Lymphocytes
Drug Therapy
Therapeutics
anaplastic lymphoma kinase

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Dunleavy, K., Piekarz, R. L., Zain, J., Janik, J. E., Wilson, W. H., O'Connor, O. A., & Bates, S. E. (2010). New strategies in peripheral T-cell lymphoma: Understanding tumor biology and developing novel therapies. Clinical Cancer Research, 16(23), 5608-5617. https://doi.org/10.1158/1078-0432.CCR-09-1995

New strategies in peripheral T-cell lymphoma : Understanding tumor biology and developing novel therapies. / Dunleavy, Kieron; Piekarz, Richard L.; Zain, Jasmine; Janik, John Edward; Wilson, Wyndham H.; O'Connor, Owen A.; Bates, Susan E.

In: Clinical Cancer Research, Vol. 16, No. 23, 01.12.2010, p. 5608-5617.

Research output: Contribution to journalReview article

Dunleavy, K, Piekarz, RL, Zain, J, Janik, JE, Wilson, WH, O'Connor, OA & Bates, SE 2010, 'New strategies in peripheral T-cell lymphoma: Understanding tumor biology and developing novel therapies', Clinical Cancer Research, vol. 16, no. 23, pp. 5608-5617. https://doi.org/10.1158/1078-0432.CCR-09-1995
Dunleavy, Kieron ; Piekarz, Richard L. ; Zain, Jasmine ; Janik, John Edward ; Wilson, Wyndham H. ; O'Connor, Owen A. ; Bates, Susan E. / New strategies in peripheral T-cell lymphoma : Understanding tumor biology and developing novel therapies. In: Clinical Cancer Research. 2010 ; Vol. 16, No. 23. pp. 5608-5617.
@article{739363a5862744e08e7a68fbd9d15899,
title = "New strategies in peripheral T-cell lymphoma: Understanding tumor biology and developing novel therapies",
abstract = "Peripheral T-cell lymphomas (PTCL) constitute a group of heterogeneous diseases that are uncommon, representing, in Western countries, only approximately 10{\%} of all non-Hodgkin lymphomas. They are typically associated with a poor prognosis compared with their B-cell counterparts and are much less well understood with respect to tumor biology, owing to their rarity and biologic heterogeneity, and to the fact that characteristic cytogenetic abnormalities are few compared with B-cell lymphomas. Although the outcome for patients with anaplastic large cell lymphoma (ALCL), particularly anaplastic lymphoma kinase (ALK)-positive ALCL, is good, other types of PTCLs are associated with a poor prognosis, even with aggressive anthracycline-based chemotherapy. In this respect, there is a need for new approaches in these diseases, and this review focuses on and explores recent experience with novel therapies in PTCL.",
author = "Kieron Dunleavy and Piekarz, {Richard L.} and Jasmine Zain and Janik, {John Edward} and Wilson, {Wyndham H.} and O'Connor, {Owen A.} and Bates, {Susan E.}",
year = "2010",
month = "12",
day = "1",
doi = "10.1158/1078-0432.CCR-09-1995",
language = "English (US)",
volume = "16",
pages = "5608--5617",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - New strategies in peripheral T-cell lymphoma

T2 - Understanding tumor biology and developing novel therapies

AU - Dunleavy, Kieron

AU - Piekarz, Richard L.

AU - Zain, Jasmine

AU - Janik, John Edward

AU - Wilson, Wyndham H.

AU - O'Connor, Owen A.

AU - Bates, Susan E.

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Peripheral T-cell lymphomas (PTCL) constitute a group of heterogeneous diseases that are uncommon, representing, in Western countries, only approximately 10% of all non-Hodgkin lymphomas. They are typically associated with a poor prognosis compared with their B-cell counterparts and are much less well understood with respect to tumor biology, owing to their rarity and biologic heterogeneity, and to the fact that characteristic cytogenetic abnormalities are few compared with B-cell lymphomas. Although the outcome for patients with anaplastic large cell lymphoma (ALCL), particularly anaplastic lymphoma kinase (ALK)-positive ALCL, is good, other types of PTCLs are associated with a poor prognosis, even with aggressive anthracycline-based chemotherapy. In this respect, there is a need for new approaches in these diseases, and this review focuses on and explores recent experience with novel therapies in PTCL.

AB - Peripheral T-cell lymphomas (PTCL) constitute a group of heterogeneous diseases that are uncommon, representing, in Western countries, only approximately 10% of all non-Hodgkin lymphomas. They are typically associated with a poor prognosis compared with their B-cell counterparts and are much less well understood with respect to tumor biology, owing to their rarity and biologic heterogeneity, and to the fact that characteristic cytogenetic abnormalities are few compared with B-cell lymphomas. Although the outcome for patients with anaplastic large cell lymphoma (ALCL), particularly anaplastic lymphoma kinase (ALK)-positive ALCL, is good, other types of PTCLs are associated with a poor prognosis, even with aggressive anthracycline-based chemotherapy. In this respect, there is a need for new approaches in these diseases, and this review focuses on and explores recent experience with novel therapies in PTCL.

UR - http://www.scopus.com/inward/record.url?scp=78650367372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650367372&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-09-1995

DO - 10.1158/1078-0432.CCR-09-1995

M3 - Review article

C2 - 21138864

AN - SCOPUS:78650367372

VL - 16

SP - 5608

EP - 5617

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 23

ER -